Tango Therapeutics is trading up 48.10% on June 8, 2026, after reporting a 92% objective response rate and 90% six-month progression-free survival in a Phase 1/2 study of vopimetostat plus daraxonrasib in MTAP-deleted pancreatic cancer, with the company planning rapid advancement to Phase 3.

Key Highlights

  • Vopimetostat plus daraxonrasib achieved a 92% objective response rate and 90% six-month progression-free survival rate in MTAP-deleted pancreatic cancer patients, with no treatment discontinuations and a generally well-tolerated safety profile.
  • Tango plans to rapidly advance the combination into Phase 3 development in first-line MTAP-deleted pancreatic cancer, targeting a chemotherapy-free treatment approach for one of oncology's most lethal diseases.

Blockbuster Phase 1/2 Data Drives the Session

Shares of Tango Therapeutics, Inc. (Nasdaq: TNGX) were trading up 48.10% on June 8, 2026, at $29.95 against a previous close of $20.22. Tango is a Boston, Massachusetts-based clinical-stage precision oncology company, founded in 2017, focused on small-molecule cancer therapies for genetically defined patient populations through a CRISPR-enabled synthetic lethality platform. With 155 employees, Revenue is generated primarily through collaboration and licensing agreements, most notably with Gilead Sciences. Lead pipeline Assets include Vopimetostat (TNG462) for MTAP-deleted cancers, TNG456 for glioblastoma, and TNG260 for STK11-mutant lung cancer.

The Clinical Data

The catalyst is positive Phase 1/2 data from the combination of vopimetostat and Revolution Medicines' daraxonrasib in patients with MTAP-deleted, RAS-mutant metastatic pancreatic ductal adenocarcinoma. Among the 12 response-evaluable PDAC patients with at least 14 weeks of follow-up, the combination achieved a 92% objective response rate (11 of 12 patients, 9 confirmed), a 90% six-month progression-free survival rate, and a 100% disease control rate. Importantly, median progression-free survival had not yet been reached, suggesting durability of response. The combination was generally well tolerated with no Grade 4 or 5 adverse events, no dose-limiting toxicities at the primary dose level, and no treatment discontinuations.

The vopimetostat plus daraxonrasib combination also achieved 100% ORR in three evaluable NSCLC patients. The vopimetostat plus zoldonrasib arm showed a 52% ORR and 74% six-month PFS in 27 PDAC patients with a 96% disease control rate.

Clinical Significance and Phase 3 Path

Pancreatic cancer remains among the most treatment-resistant oncology targets, with chemotherapy the standard of care despite limited efficacy. MTAP deletion, present in approximately 40% of pancreatic cancers, creates a synthetic lethality opportunity for PRMT5 inhibition. A 92% response rate in a heavily pre-treated population with 70% liver metastases represents a clinically meaningful result, supporting a precision-guided, chemotherapy-free approach. The company plans to finalise Phase 3 trial design for first-line pancreatic cancer in the second half of 2026.

Valuation and Risk Considerations

TNGX trades without a conventional P/E ratio, reporting a negative EPS of $0.83. The session pushed the stock to its 52-week high of $30.50. Key risks include the inherent uncertainty of Phase 3 outcomes relative to Phase 1/2 data, the complexity of regulatory approval in pancreatic cancer, and the company's pre-commercial status and cash dependency on collaboration revenue and Capital raises.

Conclusion

Tango's session advance reflects genuinely exceptional early clinical data in one of oncology's most challenging diseases, with durability signals and a clean safety profile providing a substantive foundation for the re-rating.